ASBPW — Aspire Biopharma Holdings, Inc.
NASDAQ
$0.02
+$0.00 (+17.69%)
Aspire Biopharma Holdings, Inc. (ASBPW) common stock listed on NASDAQ. It is led by Kraig T. Higginson, based in 23150 Fashion Drive, Estero, FL, United States, 33928. Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Net income was -$1.9M.
Use this ASBPW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ASBPW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ASBPW SEC filings page. Lician reads the product cache first so this HTML stays unique to Aspire Biopharma Holdings, Inc. even when a live quote feed is slow.
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
ASBPW Key Statistics
Market Cap
$0.00M
Volume
9,447
Previous Close
$0.01
Day Range
$0.02 – $0.04
EPS
$0.00
Revenue
$0.00
Net Income
-$12.54M
Gross Profit
$0.00
Free Cash Flow
$0.00
ASBPW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$12.54M | $4.46M | $3.34M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 |
Total Assets
$6.71M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$0.00
Operating Cash Flow
-$2.05M
Free Cash Flow
$0.00
Aspire Biopharma Holdings, Inc. Company Information
- Interim CEO, President & Executive Chairman of the Board
- Kraig T. Higginson
- Headquarters
- 23150 Fashion Drive, Estero, FL, United States, 33928
- Website
- aspirebiolabs.com
- Phone
- 908 987 3002
- IPO / Founded
- 2022-04-11